SGL5213

SGL5213 is a minimally absorbed, potent, and selective inhibitor of intestinal sodium-glucose cotransporter 1 (SGLT1). Its absorption is restricted to the gastrointestinal tract, where it inhibits glucose absorption from digested nutrients. By blocking SGLT1 in the gut, SGL5213 increases unabsorbed glucose delivery to the lower gastrointestinal tract and enhances post-prandial plasma levels of glucagon-like peptide-1 (GLP-1) and GLP-2 while suppressing glucose-dependent insulinotropic polypeptide (GIP). Preclinical studies have shown that SGL5213 improves post-prandial hyperglycemia, reduces obesity, liver dysfunction, insulin resistance, inflammation, and fibrosis in models of nonalcoholic fatty liver disease (NAFLD) and renal failure. It also modulates gut microbiota composition and reduces gut-derived uremic toxins. The drug is being investigated as a potential therapeutic agent for NAFLD with obesity/insulin resistance as well as chronic kidney diseases[2][4][5][6].